DSEN Research
The searchable table below lists active and completed DSEN queries by topic, scope and team. Links to study protocols, brief research abstracts summarizing the results, and to scientific publications are included as they become available.
Legend:
- CAN-AIM: the Canadian Network for Advanced Interdisciplinary Methods for Comparative Effectiveness Research
- CCNMA: The Canadian Collaboration for Drug Safety, Effectiveness and Network Meta-Analysis
- CNODES: the Canadian Network for Observational Drug Effect Studies
- DEMO: Demonstration Project
- KSRU: Knowledge Synthesis Research Unit
- MAGIC: the Methods and Applications Group for Indirect Comparisons
- NETMAN: Network Meta-Analysis Team
- PREVENT: Pharmacogenomics of Adverse Events National Team
- SEARCH: Active Surveillance and Evaluation of Adverse reactions in Canadian Healthcare
As of October 8th, 2014, the KSRU, NETMAN and CCMNA teams now form the MAGIC team. As of April 1st, 2018, SEARCH and PREVENT teams now form the SEARCH & PREVENT team.
| # | Topic | Scope | Team | Status |
|---|---|---|---|---|
| Demo 1 | Proton pump inhibitors and community-acquired pneumonia | Safety | CNODES | Completed 2013-07 |
| Demo 2 | High-dose statins and risk of acute kidney injury | Safety | CNODES | Completed 2012-01 |
| Demo 3 | Anti-tumor necrosis factor agents versus disease-modifying anti-rheumatic drugs in reducing orthopedic surgery in rheumatoid arthritis | Safety | CAN-AIM | Completed 2015-10 |
| Demo 4 | Pharmacogenomic markers of anthracycline‐induced heart failure in children | Safety | PREVENT | Completed 2015-02 |
| Demo 5 | Pharmacogenomic predictors of statin‐induced myopathy | Safety | PREVENT | Completed 2013-09 |
| Demo 6 | Inhaled corticosteroid use in children and in pregnancy | Safety | SEARCH | Completed 2015-09 |
| Demo 7 | Cognitive enhancers for Alzheimer dementia and mild cognitive impairment | Safety | KSRU | Completed 2013-09 |
| Demo 8 | Additive treatment effects in multiple treatment comparison meta-analysis | Effectiveness | NETMAN | Completed 2012-06 |
| Q10-03 | Proton pump inhibitors and myocardial infarction | Safety | CNODES | Completed 2012-01 |
| Q10-04 | Atypical antipsychotics and breast cancer | Safety | CNODES | Completed 2012-01 |
| Q10-11 | 5-HT3 antagonists and cardiac safety | Safety | KSRU | Completed 2013-12 |
| Q10-11 | 5-HT3 antagonists and cardiac safety | Safety | SEARCH | Completed 2022-04 |
| Q10-12 | Atypical antipsychotics and diabetic ketoacidosis | Safety | CNODES | Completed 2013-02 |
| Q10-18 | Proton pump inhibitors and clostridium difficile-associated diarrhea | Safety | CNODES | Completed 2012-01 |
| Q10-22b | Disease-modifying anti-rheumatic drugs in ankylosing spondylitis | Safety | CAN-AIM | Completed 2015-09 |
| Q10-22c | Atrial fibrillation related-hospitalizations | Safety | CNODES | Completed 2012-07 |
| Q10-23 | Isotretinoin-related congenital malformations | Safety | CNODES | Completed 2015-08 |
| Q11-01 | Direct oral anticoagulants for anticoagulation in atrial fibrillation | Safety & Effectiveness | CCNMA | Completed 2012-04 |
| Q11-03 | Therapies for hypertension in non-diabetic patients | Safety & Effectiveness | NETMAN | Completed 2012-10 |
| Q11-03 | Therapies for hypertension in non-diabetic patients | Safety & Effectiveness | CAN-AIM | Completed 2015-04 |
| Q11-04 | Long-acting versus intermediate-acting insulin for type 1 diabetes | Safety & Effectiveness | KSRU | Completed 2013-12 |
| Q11-04 | Long-acting versus intermediate-acting insulin for type 1 diabetes | Safety & Effectiveness | CAN-AIM | Completed 2016-02 |
| Q11-04b | Sitagliptin versus intermediate-acting insulin for type 2 diabetes | Safety & Effectiveness | KSRU | Completed 2013-10 |
| Q11-04b | Sitagliptin versus intermediate-acting insulin for type 2 diabetes | Safety & Effectiveness | CAN-AIM | Completed 2016-02 |
| Q11-05 | Interventions for smoking cessation | Safety | CCNMA | Completed 2014-12 |
| Q11-06 | Serotonin reuptake inhibitors and risks of fracture | Safety | NETMAN | Completed 2014-02 |
| Q11-06 | Serotonin reuptake inhibitors and risk of fracture | Safety | CAN-AIM | Completed 2014-01 |
| Q11-07 | Levodopa - carbidopa - entacapone and cardiovascular events | Safety | CCNMA | Completed 2014-06 |
| Q12-02 | Statins and diabetes in post myocardial infarction patients | Safety | CNODES | Completed 2014-05 |
| Q12-04 | Quetiapine and cardiomyopathy | Safety | CNODES | Completed 2016-06 |
| Q12-04T | Quetiapine and acute liver injury | Safety | CNODES | Completed 2016-07 |
| Q12-05 | Levetiracetam and developmental toxicity | Safety | KSRU | Completed 2016-11 |
| Q12-07 | Elevated prolactin levels in pediatric patients exposed to atypical antipsychotics | Safety | NETMAN | Completed 2015-06 |
| Q12-08 | Selective serotonin and norepinephrine-reuptake inhibitors and renal failure | Safety | CNODES | Completed 2013-12 |
| Q12-10 | Newer antidepressants and persistent pulmonary hypertension of the newborn | Safety | CNODES | Ongoing |
| Q12-10 | Newer antidepressants and persistent pulmonary hypertension of the newborn | Safety | CAN-AIM | Completed 2015-01 |
| Q13-01 | Darunavir and congenital malformations | Safety | KSRU | Completed 2015-04 |
| Q13-01 | Darunavir and congenital malformations | Safety | CAN-AIM | Completed 2015-02 |
| Q13-02 | Domperidone and Parkinson's disease | Safety | CNODES | Completed 2015-07 |
| Q13-03 | Safety of opioids | Safety | CNODES | Completed 2018-05 |
| Q13-05 | Optimizing chronic hepatitis C treatment | Safety & Effectiveness | SEARCH & PREVENT | Completed 2021-10 |
| Q13-06 | Incretin-based therapies and pancreatitis and/or pancreatic cancer | Safety | CNODES | Completed 2015-07 |
| Q13-4T | Incretin-based therapies and heart failure | Safety | CNODES | Completed 2015-10 |
| Q14-01 | Pharmacological treatments for rheumatoid arthritis | Safety & Effectiveness | CCNMA | Completed 2018-04 |
| Q14-01 | Pharmacological treatments for rheumatoid arthritis | Safety & Effectiveness | CNODES | Completed 2021-10 |
| Q14-02 | Direct oral anticoagulants for the treatment of venous thromboembolic events | Safety & Effectiveness | CCNMA | Completed 2016-02 |
| Q14-02b | Direct oral anticoagulants for the treatment of venous thromboembolic events | Safety & Effectiveness | CNODES | Completed 2016-12 |
| Q14-02b | Direct oral anticoagulants for the treatment of venous thromboembolic events | Safety & Effectiveness | SEARCH | Ongoing |
| Q14-02b | Direct oral anticoagulants for the treatment of venous thromboembolic events | Safety & Effectiveness | PREVENT | Ongoing |
| Q14-02c | Direct oral anticoagulants for the prevention of venous thromboembolic events in the hospital setting | Safety & Effectiveness | MAGIC | Completed 2016-12 |
| Q14-05 | Efficacy of modified released methylphenidate linked to pharmacokinetic profile | Efficacy | CCNMA | Completed 2015-01 |
| Q15-01 | Drugs for chronic Hepatitis C | Safety & Effectiveness | MAGIC | Completed 2015-08 |
| Q15-04 | Dual antiplatelet therapy following percutaneous coronary intervention | Effectiveness | MAGIC | Completed 2017-08 |
| Q15-04T | Cognitive enhancers for treating Alzheimer dementia | Safety | MAGIC | Completed 2016-06 |
| Q15-06 | Anti–vascular endothelial growth factor drugs for retinal conditions | Effectiveness | MAGIC | Completed 2016-05 |
| Q15-07 | Treatments for latent tuberculosis infection | Safety | MAGIC | Completed 2016-03 |
| Q15-08 | Conditioning regimens for allogeneic hematopoietic cell transplantation | Safety & Effectiveness | MAGIC | Completed 2016-12 |
| Q15-09 | Prevention and treatment of graft versus host disease after allogeneic hematopoietic cell transplantation | Safety & Effectiveness | MAGIC | Completed 2016-12 |
| Q15-10 | Infection management and allogeneic hematopoietic cell transplantation | Safety & Effectiveness | MAGIC | Completed 2016-12 |
| Q15-11 | Intravitreal bevacizumab for retinal conditions | Safety | CAN-AIM | Completed 2018-12 |
| Q15-14 | New drugs for type 2 diabetes | Effectiveness | MAGIC | Ongoing |
| Q16-01 | Utilization of social media for Canadian pharmacovigilance | Safety | MAGIC | Completed 2017-04 |
| Q16-01 | Utilization of social media for Canadian pharmacovigilance | Safety | CAN-AIM | Completed 2019-10 |
| Q16-02 | Use of systemic oral fluoroquinolones | Safety | CNODES | Completed 2018-11 |
| Q16-03 | Preventable adverse drug reactions as percentage of total | Safety | MAGIC | Completed 2018-04 |
| Q16-03 | Preventable adverse drug reactions as percentage of total | Safety | CAN-AIM | Completed 2020-06 |
| Q16-04 | Early detection of pancreatitis | Contextual | MAGIC | Completed 2018-08 |
| Q16-06 | Crizotinib and incidence of death | Safety | MAGIC | Completed 2018-10 |
| Q16-07 | Options to support appropriate prescribing | Effectiveness | MAGIC | Completed 2016-12 |
| Q16-07 | Options to support appropriate prescribing | Effectiveness | CAN-AIM | Completed 2017-05 |
| Q16-08 | Ondansetron and fetal abnormalities | Safety | CNODES | Completed 2019-11 |
| Q16-08 | Ondansetron and fetal abnormalities | Safety | CAN-AIM | Completed 2017-11 |
| Q16-09 | Low dose fluconazole and adverse pregnancy outcomes | Safety | CNODES | Completed 2020-05 |
| Q16-09 | Low dose fluconazole and adverse pregnancy outcomes | Safety | CAN-AIM | Completed 2018-05 |
| Q16-10 | Domperidone and breastfeeding women | Safety | CNODES | Completed 2019-07 |
| Q16-11 | Appropriate use of interventions in insomnia | Safety & Effectiveness | MAGIC | Completed 2018-05 |
| Q16-12 | Herpes zoster vaccine in individuals 50 years of age or older | Safety & Effectiveness | MAGIC | Completed 2018-05 |
| Q16-13 | Direct oral anticoagulants and atrial fibrillation | Safety & Effectiveness | CNODES | Completed 2019-07 |
| Q17-01 | International collaboration pilot: Direct oral anticoagulants and atrial fibrillation | Safety & Effectiveness | CNODES | Ongoing |
| Q17-02 | Common Data Model pilot | Safety | CNODES | Ongoing |
| Q17-03 | Safety of Bowel Cleansers | Safety | MAGIC | Completed 2019-03 |
| Q17-03 | Safety of Bowel Cleansers | Safety | CNODES | Completed 2019-05 |
| Q17-04 | Comparative Efficacy and Safety of Insulin Preparations and Biosimilar Insulins for Type 1 Diabetes Mellitus | Safety & Comparative Effectiveness | MAGIC | Ongoing |
| Q17-05 | Comparative Safety and Effectiveness of Biosimilar and Legacy Drugs | Safety & Comparative Effectiveness | CAN-AIM | Ongoing |
| Q17-06 | Cancer and Immunomodulators | Safety | MAGIC | Completed 2018-06 |
| Q17-08 | Appropriate Use Organizations | Comparative Effectiveness | MAGIC | Completed 2019-04 |
| Q18-01 | Associations between industry incentives received by healthcare professionals and impact on drug prescribing and patient outcomes | Contextual | MAGIC | Completed 2018-06 |
| Q18-04 | Options to Support Appropriate Opioids Prescribing | Contextual | CAN-AIM | Completed 2020-03 |
| Q18-06 | Risk of Macrovascular Events and Heart Failure Associated Medication Used to Treat Individuals with Type 2 Diabetes | Comparative Effectiveness | CNODES | Completed 2019-11 |
| Q18-09 | Risk of Urinary Tract Infection Associated with Medication Used to Treat Individuals with Type 2 Diabetes | Comparative Effectiveness | CNODES | Completed 2019-11 |
| Q18-10 | Risk of Amputation Associated with Medication Used to Treat Individuals with Type 2 Diabetes | Comparative Effectiveness | CNODES | Completed 2019-11 |
| Q18-11 | Risk of Diabetic Ketoacidosis Associated with Medication Used to Treat Individuals with Type 2 Diabetes | Comparative Effectiveness | CNODES | Completed 2019-11 |
| Q18-12 | The benefits and harms of drugs used for treatment or prevention of osteoporosis in postmenopausal women | Safety & Effectiveness | MAGIC | Completed 2020-09 |
| Q19-01 | Methods, tools and guidelines for the active surveillance of health products | Contextual | MAGIC |
Completed 2024-02 |
| Q19-03 | Active surveillance for safety and effectiveness of health products: Canadian multi-province cohorts of pregnant women and children | Contextual | CAN-AIM | Completed 2021-07 |
| Q19-04 | Common data model – Phase II | Contextual | CNODES | Completed 2021-02 |
| Q19-05 | Hydrochlorothiazides and the risk of skin cancer | Safety | CNODES | Completed 2021-06 |
| Q19-05 | Hydrochlorothiazides and the risk of skin cancer | Safety | CAN-AIM | Completed 2022-08 |
| Q19-06 | Cough and cold products containing opioids | Contextual | CAN-AIM | Completed 2022-07 |
| Q19-06 | Cough and cold products containing opioids | Contextual | SEARCH & PREVENT | Completed 2022-07 |
| Q19-07a | Effectiveness of influenza vaccines in adults 65 years of age and older | Effectiveness | CAN-AIM | Completed 2021-01 |
| Q19-07a | Effectiveness of influenza vaccines in adults 65 years of age and older | Effectiveness | MAGIC | Completed |
| Q19-07b | Cost-effectiveness of influenza vaccines in adults 65 years of age and older | Contextual | MAGIC | Completed |
| Q19-08 | Safety of influenza vaccine for women and their newborns if received during pregnancy | Safety | CAN-AIM | Completed 2020-05 |
| Q19-08 | Safety of influenza vaccine for women and their newborns if received during pregnancy | Safety | MAGIC | Completed 2021-09 |
| Q20-01 | Stem Cell Therapies | Safety & Effectiveness | CAN-AIM | Completed 2023-06 |
| Q20-01 | Stem Cell Therapies | Safety & Effectiveness | MAGIC | Ongoing |
| Q20-02 | Utilization of angiotensin receptor blockers (ARBs) in Canada | Common Data Model | CNODES |
Completed 2023-08 |
| Q20-03 | Safety of 1st generation smallpox vaccine in the contraindicated populations | Safety | MAGIC |
Completed 2024-04 |
| Q20-04 | Efficacy and safety of treatments (antivirals and antibodies) for coronavirus (CoV) | Safety & Effectiveness | MAGIC | Completed 2020-02 |
| Q20-05 | SSRI/SNRIs and Sexual Dysfunction | Safety | CNODES | Completed 2020-03 |
| Q20-06 | Managing chronic pain, mental illness, and problematic substance use | Effectiveness | MAGIC | Completed 2020-04 |
| Q20-07 | Effectiveness and safety of antibiotic prophylaxis for persons exposed to cases of invasive group A streptococcal disease (iGAS) | Safety & Comparative Effectiveness | CAN-AIM | Completed 2021-04 |
| Q20-07 | Effectiveness and safety of antibiotic prophylaxis for persons exposed to cases of invasive group A streptococcal disease (iGAS) | Safety & Comparative Effectiveness | MAGIC | Completed 2021-10 |
| Q20-08 | Drug Utilization in Canadian Children | Safety & Effectiveness | CIHI | Completed 2020-04 |
| Q20-09 | Expanded review of managing chronic pain in those concurrently diagnosed with mental illness and/or problematic substance use [expansion of DSEN Q20-06] | Effectiveness | MAGIC | Completed 2020-07 |
| Q20-10 | An investigation of effective strategies to reduce the risk of transitioning from acute to chronic pain | Effectiveness | MAGIC | Completed 2020-04 |
| Q20-11 | An expanded investigation of effective strategies to reduce the risk of acute pain transitioning to chronic pain following injury, trauma, or surgery [expansion of DSEN Q20-10] | Effectiveness | MAGIC | Completed 2020-07 |
| Q20-12 | Prescription patterns of ranitidine in Canada | Utilization | CAN-AIM |
Completed 2021-08 |
| Q20-12 | Prescription patterns of ranitidine in Canada | Utilization | CNODES |
Completed 2021-05 |
| Q20-13 | Rapid review of the effectiveness and safety of treatments for COVID-19 and other coronaviruses that cause serious respiratory tract infections | Safety & Effectiveness | MAGIC | Completed 2020-05 |
| Q20-14 | The influence of the COVID-19 pandemic on quality assessment instruments and risk of bias tools for randomized clinical trials as well as guidelines and recommendations for the development of protocols and the reporting of trials. | Other | MAGIC with CAN-AIM SEARCH & PREVENT CNODES |
Completed 2020-05 |
| Q20-15 | Safety and effectiveness of dose-sparing strategies for seasonal influenza vaccine: Rapid review of intradermal administration of the inactivated influenza vaccine | Safety & Effectiveness | MAGIC | Completed 2020-07 |
| Q20-16 | Safety and effectiveness of dose-sparing strategies for seasonal influenza vaccine: Rapid scoping review of fractional dosing of the intramuscular influenza vaccine | Safety & Effectiveness | MAGIC | Completed 2020-07 |
| Q20-18 | The benefits and harms of drugs used for treatment or prevention of osteoporosis in postmenopausal women [Expansion of DSEN Q18-12] | Safety & Effectiveness | MAGIC | Completed 2020-11 |
| Q20-19 | Allogeneic mesenchymal stem cell therapy for COVID-19 and other viral and bacterial-induced acute respiratory distress syndrome: a clinical systematic review of donor, recipient, and therapeutic characteristics and efficacy and safety. | Safety and Effectiveness | MAGIC | Ongoing |
| Q20-21 | A Natural History of Coagulopathy and Characteristics of its Treatment in COVID-19 Patients | Safety, Effectiveness & Other | CNODES |
Completed 2023-10 |
| Q20-22 | The effect of opioid drug discontinuations or shortages on patient care, outcomes and the market. | Safety and Effectiveness | MAGIC | Completed 2021-06 |
| Q20-23 | Active surveillance methods and COVID-19 | Other | MAGIC | Completed 2023-09 |
| Q21-01 | COVID-19 vaccine in immunosuppressed adults with autoimmune diseases | Safety and Effectiveness | CAN-AIM | Pursued outside DSEN |
| Q21-02 | Patterns of Steroid Utilization in COVID-19 Patients | Safety, Effectiveness & Other | CNODES | Completed 2023-12 |
| Q21-03 | COVID-19 infection and medicines in pregnancy | Safety, Effectiveness & Other | CAN-AIM | Ongoing |
| Q21-04 | Reliability of COVID-19 case definitions in administrative and clinical databases. | Other | CAN-AIM |
Completed 2022-08 |
| Q21-04 | Reliability of COVID-19 case definitions in administrative and clinical databases. | Other | CNODES |
Completed 2022-05 |
| Q21-05 | Hydromorphone controlled release and the risk of infectious endocarditis, hepatitis C virus and human immunodeficiency virus infections in people who inject drugs | Safety | MAGIC | Completed 2022-08 |
| Q21-05 | Hydromorphone controlled release and the risk of infectious endocarditis, hepatitis C virus and human immunodeficiency virus infections in people who inject drugs | Safety | CAN-AIM | Completed 2023-07 |
| Q21-06 | Safety and immunogenicity of COVID-19 vaccines in pediatric populations with systemic immune-mediated diseases | Safety, Comparative Effectiveness, and Other | CAN-AIM | Completed 2022-08 |
| Q22-02 | Assessing the potential for additive toxicity arising from the combined use of immune checkpoint inhibitors and of tyrosine kinase inhibitors | Safety and effectiveness | MAGIC | Completed 2024-03 |
- Date modified: